Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12595280 | Phosphoramidates for the treatment of hepatitis B virus | 🖼🧊📄§ | 2026-04-07 | 2044-04-11 | 0 | 31 |
| 12595285 | LMP-1 expressing cells and methods of use thereof | 🖼🧊📄§ | 2026-04-07 | 2042-05-13 | 0 | 31 |
| 12595477 | Complement Factor B-modulating compositions and methods of use thereof | 🖼🧊📄§ | 2026-04-07 | 2042-11-23 | 0 | 31 |
| 12595250 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | 🖼🧊📄§ | 2026-04-07 | 2042-06-15 | 0 | 31 |
| 12595243 | Modulators of extracellular signal-regulated kinase | 🖼🧊📄§ | 2026-04-07 | 2044-10-18 | 0 | 31 |
| 12594272 | 2-bromo-lysergic acid diethylamide for substance abuse | 🖼🧊📄§ | 2026-04-07 | 2041-03-25 | 0 | 31 |
| 12595300 | Anti-human P40 protein domain antibody and use thereof | 🖼🧊📄§ | 2026-04-07 | 2040-07-28 | 0 | 31 |
| 12595293 | Anti-follicle stimulating hormone receptor antibodies | 🖼🧊📄§ | 2026-04-07 | 2039-08-09 | 0 | 31 |
| 12595267 | Preparation method for amide compound and application thereof in field of medicine | 🖼🧊📄§ | 2026-04-07 | 2040-03-24 | 0 | 31 |
| 12595232 | DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor | 🖼🧊📄§ | 2026-04-07 | 2041-02-16 | 0 | 31 |
| 12595302 | CLDN18.2 binding molecule | 🖼🧊📄§ | 2026-04-07 | 2040-05-21 | 0 | 31 |
| 12595517 | Method to treat and stratify a patient suffering from a cancer | 🖼🧊📄§ | 2026-04-07 | 2041-09-13 | 0 | 31 |
| 12594308 | Methods of preparing a postbiotic composition | 🖼🧊📄§ | 2026-04-07 | 2044-10-08 | 0 | 31 |
| 12595307 | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors | 🖼🧊📄§ | 2026-04-07 | 2041-06-09 | 0 | 31 |
| 12594245 | Dry powder formulations for messenger RNA | 🖼🧊📄§ | 2026-04-07 | 2042-05-16 | 0 | 31 |
| 12595469 | Treatment of retinitis pigmentosa using improved engineered meganucleases | 🖼🧊📄§ | 2026-04-07 | 2041-05-11 | 0 | 31 |
| 12596122 | LILRB2 antibodies and uses thereof | 🖼🧊📄§ | 2026-04-07 | 2041-01-28 | 0 | 31 |
| 12595481 | Methods and compositions for neuroprotection | 🖼🧊📄§ | 2026-04-07 | 2040-11-25 | 0 | 31 |
| 12595263 | Pyrazolopyrimidine compound used as ATR kinase inhibitor | 🖼🧊📄§ | 2026-04-07 | 2041-07-13 | 0 | 31 |
| 12595265 | Inhibitors of activin receptor-like kinase | 🖼🧊📄§ | 2026-04-07 | 2043-04-20 | 0 | 31 |
| 12595259 | Aminopyridine compound | 🖼🧊📄§ | 2026-04-07 | 2041-06-17 | 0 | 31 |
| 12595275 | Fluorine-containing compound and anti-cancer medical use thereof | 🖼🧊📄§ | 2026-04-07 | 2040-05-12 | 0 | 31 |
| 12595289 | Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2 | 🖼🧊📄§ | 2026-04-07 | 2039-11-28 | 0 | 31 |
| 12595306 | TREM2 stabilizing antibodies | 🖼🧊📄§ | 2026-04-07 | 2044-12-23 | 0 | 31 |
| 12595305 | TREM2 stabilizing antibodies | 🖼🧊📄§ | 2026-04-07 | 2042-09-23 | 0 | 31 |
| 12595304 | Antibodies specific to glycosylated LAG3 and methods of use thereof | 🖼🧊📄§ | 2026-04-07 | 2040-10-09 | 0 | 31 |
| 12595309 | Compositions and methods for treatment of thyroid eye disease | 🖼🧊📄§ | 2026-04-07 | 2044-11-08 | 0 | 31 |
| 12595312 | CD133-binding agents and uses thereof | 🖼🧊📄§ | 2026-04-07 | 2041-10-26 | 0 | 31 |
| 12594248 | Stress management in human subjects in need thereof | 🖼🧊📄§ | 2026-04-07 | 2041-01-13 | 0 | 31 |
| 12594251 | Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19 | 🖼🧊📄§ | 2026-04-07 | 2041-10-14 | 0 | 31 |
| 12594253 | HIV inhibitors | 🖼🧊📄§ | 2026-04-07 | 2039-07-24 | 0 | 31 |
| 12594252 | Methods for treating inflammatory skin conditions | 🖼🧊📄§ | 2026-04-07 | 2042-06-20 | 0 | 31 |
| 12594258 | Inhibitors of MHC-I Nef downmodulation for treating HIV | 🖼🧊📄§ | 2026-04-07 | 2040-12-16 | 0 | 31 |
| 12594263 | CBL inhibitors and compositions for expansion of immune cells | 🖼🧊📄§ | 2026-04-07 | 2040-09-23 | 0 | 31 |
| 12594260 | Topical formulations for infections | 🖼🧊📄§ | 2026-04-07 | 2044-06-28 | 0 | 31 |
| 12594270 | Schizophrenic disorder treatment using combination therapy | 🖼🧊📄§ | 2026-04-07 | 2040-10-21 | 0 | 31 |
| 12594267 | Capsid inhibitors for the treatment of HIV | 🖼🧊📄§ | 2026-04-07 | 2044-02-27 | 0 | 31 |
| 12594271 | Combination therapy for cancer | 🖼🧊📄§ | 2026-04-07 | 2040-11-05 | 0 | 31 |
| 12594280 | Antiviral compositions for treating the flu | 🖼🧊📄§ | 2026-04-07 | 2042-05-31 | 0 | 31 |
| 12594274 | Method for preparing a crystalline form of rabeximod | 🖼🧊📄§ | 2026-04-07 | 2041-06-10 | 0 | 31 |
| 12594281 | Pharmaceutical dosage forms and methods of use | 🖼🧊📄§ | 2026-04-07 | 2045-05-16 | 0 | 31 |
| 12594285 | Compositions and methods for protecting against airborne pathogens and irritants | 🖼🧊📄§ | 2026-04-07 | 2041-10-08 | 0 | 31 |
| 12594282 | Use of small molecule compounds in the treatment of diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury | 🖼🧊📄§ | 2026-04-07 | 2041-02-26 | 0 | 31 |
| 12594290 | IP and IP analogs dosage regimens for the treatment of ectopic calcifications | 🖼🧊📄§ | 2026-04-07 | 2045-02-27 | 0 | 31 |
| 12594286 | Immunodulating small molecules | 🖼🧊📄§ | 2026-04-07 | 2042-05-25 | 0 | 31 |
| 12594289 | Potentiation of antibiotic effect | 🖼🧊📄§ | 2026-04-07 | 2043-08-11 | 0 | 31 |
| 12594291 | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen | 🖼🧊📄§ | 2026-04-07 | 2039-10-31 | 0 | 31 |
| 12594294 | Therapeutic and prophylactic agent for glioma, brain tumor malignancy marker, brain tumor prognostic marker, method for determining malignancy and prognosis of brain tumor and antibody inhibiting tumor proliferation | 🖼🧊📄§ | 2026-04-07 | 2039-12-27 | 0 | 31 |
| 12594297 | Composition comprising hyaluronic acid and pluronic for preventing or treating articular and cartilage injury | 🖼🧊📄§ | 2026-04-07 | 2040-08-03 | 0 | 31 |
| 12594304 | Method for treating liver cirrhosis by using composition comprising mesenchymal stem cell. extracellular vesicle produced by mesenchymal stem cell, and growth factor | 🖼🧊📄§ | 2026-04-07 | 2043-10-04 | 0 | 31 |